Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Conditions
Interventions
TAS-119
Paclitaxel
Locations
4
United States
University of Colorado Hospital Anschutz Cancer Pavilion
Aurora, Colorado, United States
Washington University School of Medicine Division of Oncology Siteman Cancer Center
St Louis, Missouri, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Vanderbilt Ingram Cancer Center
Nashville, Tennessee, United States
Start Date
August 1, 2014
Primary Completion Date
July 1, 2018
Completion Date
July 1, 2018
Last Updated
September 5, 2024
NCT07360314
NCT07403721
NCT07539285
NCT07524348
NCT03093116
NCT06898450
Lead Sponsor
Taiho Oncology, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions